Eshan Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eshan Ahmad has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Aamna Raheel Sheikh
Foundation University Medical College, Rawalpindi, Pakistan
2 shared publications - Ahmed Ali Khan
Foundation University Medical College, Islamabad, Pakistan
2 shared publications - Asher Tariq
Foundation University Medical College, Islamabad, Pakistan
2 shared publications - Atifa Kanwal
Shaheed Mohtarma Benazir Bhutto Medical College, Lyari, Karachi, Pakistan
2 shared publications - Eshal Fatima
Aga Khan Medical College, Karachi, Pakistan
2 shared publications - Laiba Zaheer
Foundation University Medical College, Islamabad, Pakistan
2 shared publications
Latest Publications
- 29 July 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (10) , 2605-2615
Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis
- 29 July 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (10) , 2605-2615
Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis
- 30 December 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 116, 104808
Effect of quetiapine versus haloperidol on delirium severity in hospitalized adults: A systematic review and meta‑analysis
- 30 December 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 116, 104808
Effect of quetiapine versus haloperidol on delirium severity in hospitalized adults: A systematic review and meta‑analysis
- Open Access
- 11 November 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 360
Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: a systematic review of monoclonal antibodies and fusion proteins in combination strategies
Background The CD47-SIRPα axis is a key innate immune checkpoint that enables tumor cells to evade macrophage-mediated clearance. CD47 is overexpressed in a spectrum of hematologic malignancies, contributing to poor outcomes, particularly in high-risk biological subgroups. While early clinical trials of CD47 blockade demonstrated limited efficacy as monotherapy, combination strategies have emerged as promising approaches. This systematic review synthesizes the current clinical evidence on the outcomes and safety of CD47-targeted monoclonal antibodies and fusion proteins administered in combination with regimens for hematologic malignancies. Methods A comprehensive search of PubMed/MEDLINE, Embase, Cochrane Library, and clinical trial registries was conducted until May 2025. Prospective interventional trials evaluating CD47-targeted agents in combination with systemic therapies for hematologic malignancies were included. The outcomes of interest were response rate, survival, and safety. The methodological quality was assessed using the MINORS. The protocol for this review was prospectively registered in the PROSPERO International Prospective Register of Systematic Reviews (registration number: CRD420251071435). Results Nine prospective clinical trials enrolling over 800 patients were included in this study. In patients with higher-risk myelodysplastic syndromes (MDS), the combination of magrolimab and azacitidine achieved an overall response rate (ORR) of 63%, with a complete remission (CR) rate exceeding 30%, including in patients with TP53-mutant disease. In untreated AML, the ORR reached 65%, with durable responses observed in patients with adverse cytogenetic mutations. In relapsed/refractory diffuse large B-cell lymphoma (DLBCL), combinations of CD47 blockade with anti-CD20 antibodies ± chemotherapy or novel immunotherapeutics achieved an ORR of 33–52%, with CR rates of up to 33%. In indolent non-Hodgkin lymphoma, magrolimab plus rituximab produced an ORR of 74% and a CR of 39%, including in rituximab-refractory patients. Preliminary data on multiple myeloma have demonstrated encouraging activity in triple-class refractory diseases. Across malignancies, CD47-targeted combinations were well tolerated, with manageable anemia and no unexpected toxicity. Conclusions CD47-targeted combinations demonstrate encouraging early phase efficacy and manageable safety in hematologic malignancies, with signals of benefit in higher-risk MDS, TP53-mutant AML, relapsed/refractory DLBCL, and rituximab-refractory iNHL. However, recent Phase III trials in newly diagnosed AML Daver et al. [27], and Zeidner et al. [26] did not confirm this benefit, underscoring that CD47 blockade remains investigational and requires validation in rigorously designed randomized studies.
- 11 November 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 360
Open AccessClinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: a systematic review of monoclonal antibodies and fusion proteins in combination strategies
Background The CD47-SIRPα axis is a key innate immune checkpoint that enables tumor cells to evade macrophage-mediated clearance. CD47 is overexpressed in a spectrum of hematologic malignancies, contributing to poor outcomes, particularly in high-risk biological subgroups. While early clinical trials of CD47 blockade demonstrated limited efficacy as monotherapy, combination strategies have emerged as promising approaches. This systematic review synthesizes the current clinical evidence on the outcomes and safety of CD47-targeted monoclonal antibodies and fusion proteins administered in combination with regimens for hematologic malignancies. Methods A comprehensive search of PubMed/MEDLINE, Embase, Cochrane Library, and clinical trial registries was conducted until May 2025. Prospective interventional trials evaluating CD47-targeted agents in combination with systemic therapies for hematologic malignancies were included. The outcomes of interest were response rate, survival, and safety. The methodological quality was assessed using the MINORS. The protocol for this review was prospectively registered in the PROSPERO International Prospective Register of Systematic Reviews (registration number: CRD420251071435). Results Nine prospective clinical trials enrolling over 800 patients were included in this study. In patients with higher-risk myelodysplastic syndromes (MDS), the combination of magrolimab and azacitidine achieved an overall response rate (ORR) of 63%, with a complete remission (CR) rate exceeding 30%, including in patients with TP53-mutant disease. In untreated AML, the ORR reached 65%, with durable responses observed in patients with adverse cytogenetic mutations. In relapsed/refractory diffuse large B-cell lymphoma (DLBCL), combinations of CD47 blockade with anti-CD20 antibodies ± chemotherapy or novel immunotherapeutics achieved an ORR of 33–52%, with CR rates of up to 33%. In indolent non-Hodgkin lymphoma, magrolimab plus rituximab produced an ORR of 74% and a CR of 39%, including in rituximab-refractory patients. Preliminary data on multiple myeloma have demonstrated encouraging activity in triple-class refractory diseases. Across malignancies, CD47-targeted combinations were well tolerated, with manageable anemia and no unexpected toxicity. Conclusions CD47-targeted combinations demonstrate encouraging early phase efficacy and manageable safety in hematologic malignancies, with signals of benefit in higher-risk MDS, TP53-mutant AML, relapsed/refractory DLBCL, and rituximab-refractory iNHL. However, recent Phase III trials in newly diagnosed AML Daver et al. [27], and Zeidner et al. [26] did not confirm this benefit, underscoring that CD47 blockade remains investigational and requires validation in rigorously designed randomized studies.
- 3 November 2025
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 19 (1) , 1-15
Da Vinci Xi versus laparoscopic transabdominal preperitoneal (TAPP) repair of inguinal hernia: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
Transabdominal preperitoneal (TAPP) repair is the gold standard for minimally invasive inguinal hernia surgery. With the advent of robotic surgery, robotic-assisted TAPP (r-TAPP) has emerged as an alternative to conventional laparoscopic TAPP (l-TAPP), although comparative evidence remains limited. We conducted a prospectively registered systematic review and meta-analysis (PROSPERO ID: CRD420251154089) of randomized controlled trials comparing r-TAPP and l-TAPP in adults with inguinal hernias. We searched MEDLINE, Embase, Cochrane CENTRAL, Web of Science, Scopus, ClinicalTrials.gov, WHO ICTRP, and Google Scholar from inception to September 2025 for relevant studies. The primary outcomes were operative duration and postoperative complications within 30 days. The secondary outcomes included seroma, hematoma, urinary retention, and readmission rates. A random-effects meta-analysis was performed using RevMan 5.4. Evidence certainty was assessed using the GRADE methodology. Three randomized controlled trials encompassing 379 patients (196 r-TAPP and 183 l-TAPP) met the inclusion criteria. Overall operative time showed no significant difference (MD 0.59 min, 95% CI -23.67 to 24.85, I²=98%). However, sensitivity analysis removing the heterogeneity-driving study revealed r-TAPP advantage (-15.20 min, 95% CI -18.58 to -11.82, p < 0.00001). No statistically significant differences were observed for any postoperative complication (OR 0.84, 95% CI 0.19–3.79), seroma (OR 1.00, 95% CI 0.13–8.01), hematoma (OR 0.64, 95% CI 0.08–5.30), urinary retention (OR 0.55, 95% CI 0.17–1.76), or readmission (OR 0.51, 95% CI 0.02–12.14). GRADE certainty ranged from low to very low because of imprecision and inconsistency. Across three randomized trials, r-TAPP and l-TAPP showed similar short-term safety with no confirmed difference in operative time. Substantial heterogeneity—likely related to trial design and experience—limits certainty, and publication bias cannot be reliably assessed with so few studies. Larger, multicenter RCTs with standardized protocols and definitions are needed to establish comparative effectiveness.
- 3 November 2025
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 19 (1) , 1-15
Da Vinci Xi versus laparoscopic transabdominal preperitoneal (TAPP) repair of inguinal hernia: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
Transabdominal preperitoneal (TAPP) repair is the gold standard for minimally invasive inguinal hernia surgery. With the advent of robotic surgery, robotic-assisted TAPP (r-TAPP) has emerged as an alternative to conventional laparoscopic TAPP (l-TAPP), although comparative evidence remains limited. We conducted a prospectively registered systematic review and meta-analysis (PROSPERO ID: CRD420251154089) of randomized controlled trials comparing r-TAPP and l-TAPP in adults with inguinal hernias. We searched MEDLINE, Embase, Cochrane CENTRAL, Web of Science, Scopus, ClinicalTrials.gov, WHO ICTRP, and Google Scholar from inception to September 2025 for relevant studies. The primary outcomes were operative duration and postoperative complications within 30 days. The secondary outcomes included seroma, hematoma, urinary retention, and readmission rates. A random-effects meta-analysis was performed using RevMan 5.4. Evidence certainty was assessed using the GRADE methodology. Three randomized controlled trials encompassing 379 patients (196 r-TAPP and 183 l-TAPP) met the inclusion criteria. Overall operative time showed no significant difference (MD 0.59 min, 95% CI -23.67 to 24.85, I²=98%). However, sensitivity analysis removing the heterogeneity-driving study revealed r-TAPP advantage (-15.20 min, 95% CI -18.58 to -11.82, p < 0.00001). No statistically significant differences were observed for any postoperative complication (OR 0.84, 95% CI 0.19–3.79), seroma (OR 1.00, 95% CI 0.13–8.01), hematoma (OR 0.64, 95% CI 0.08–5.30), urinary retention (OR 0.55, 95% CI 0.17–1.76), or readmission (OR 0.51, 95% CI 0.02–12.14). GRADE certainty ranged from low to very low because of imprecision and inconsistency. Across three randomized trials, r-TAPP and l-TAPP showed similar short-term safety with no confirmed difference in operative time. Substantial heterogeneity—likely related to trial design and experience—limits certainty, and publication bias cannot be reliably assessed with so few studies. Larger, multicenter RCTs with standardized protocols and definitions are needed to establish comparative effectiveness.